Highest-materiality recent filing
Merger closed July 21, 2026; shareholders received $13.25 per share in cash.
Cross Country Healthcare stockholders approve merger to go private; expected Q3 2026 close
Proposal to adopt merger agreement approved: 23,356,105 for, 12,309 against, 10,439 abstentions.
HSR Act waiting period for the merger and Locums Transaction expired June 22, 2026, satisfying a major condition.
Cross Country Healthcare to be acquired by Knox Lane for $13.25/share in $437M all-cash deal
Deal valued at ~$437M, with stockholders receiving $13.25 per share in cash.
Cross Country Healthcare Q1 2026 revenue down 18% YoY, net loss widens to $4.3M
Revenue $241.1M, down 18% YoY; gross profit margin 19.7%, down 30 bps.
Cross Country Healthcare Q4 2025 revenue down 24% YoY; net loss of $82.9M
Revenue $236.8M in Q4 2025, down 24% YoY; full-year revenue $1.054B, down 22%.
Cross Country CEO Martins departs; co-founder Clark returns as CEO after Aya deal termination
CEO John Martins separated effective Dec 14, 2025; receives severance of 2-year base salary ($875K) plus average bonus.
Cross Country Healthcare merger with Aya Healthcare terminated; to receive $20M fee; starts buybacks
Merger agreement with Aya Healthcare terminated effective Dec 4, 2025 after failing to close by Dec 3, 2025 end date.
Cross Country Healthcare Q3 revenue $250M, down 21% YoY; net loss $4.8M
Revenue $250.1M, down 21% YoY and 9% sequentially; gross margin 20.4% flat.
Cross Country Healthcare extends merger deadline to Dec 3, 2025; FTC compliance certified
Merger end date automatically extended from Sept 3, 2025 to Dec 3, 2025 per the Merger Agreement.
Cross Country Healthcare Q2 revenue down 19% YoY, net loss of $6.7M, negative adjusted EPS
Revenue $274.1M, down 19% YoY; gross margin 20.4%, down 40 bps.
Cross Country Q1 revenue down 23% YoY to $293.4M; adjusted EPS $0.06
Revenue $293.4M, down 23% YoY; net loss $490K ($0.02 loss per share).
Cross Country Healthcare reports Q4 2024 revenue down 25% YoY, net loss of $3.8M
Q4 2024 revenue $309.9M, down 25% YoY and 2% sequentially.
Stockholders approve Aya Healthcare acquisition; merger expected H2 2025
Over 78% of shares voted; 25.66M votes for Merger Agreement, 11K against.
Cross Country Healthcare receives FTC Second Request for Aya merger; close expected H2 2025
FTC issued Second Request under HSR Act, extending waiting period until 30 days after substantial compliance by both parties.
Aya Healthcare to acquire Cross Country Healthcare for $18.61/share (~$615M all-cash)
Stockholders receive $18.61 per share in cash, a 67% premium to Dec 3 closing price.
Cross Country Healthcare Q3 revenue down 29% YoY to $315M; EPS $0.08
Revenue of $315.1M fell 29% YoY; gross margin 20.4%, down 160 bps.
Cross Country Q2 revenue down 37% YoY to $339.8M; net loss of $16.0M
Revenue $339.8M, down 37% YoY and 10% sequentially; gross margin 20.8% (-200 bps YoY).
Cross Country Healthcare customer files Chapter 11; expects $20M bad debt charge in Q2 2024
Customer filed Chapter 11 bankruptcy on May 6, 2024.
Cross Country Healthcare Q1 revenue down 39% YoY to $379M; net income falls 91%
Revenue $379.2M, down 39% YoY and 8% sequentially.
Cross Country Healthcare Q4 net income drops 77% on 34% revenue decline
Q4 2023 revenue $414M, down 34% YoY and 6% sequentially; full year revenue $2.02B, down 28%.
Revenue of $442.3M, down 30% from Q3 2022 and 18% from Q2 2023.
Cross Country's ABL covenant becomes springing, tied to excess availability thresholds
Amendment No. 6 changes fixed charge coverage ratio from maintenance to springing covenant triggered when excess availability falls below greater of 15% of loan cap or $24M.
On February 14, 2024, Cross Country Healthcare, Inc. (the “Company”) entered into a separation agreement (the “Agreement”) with Daniel J. White, Chief Commercial Officer. Under the Agreement, Mr. White will depart the Company on March 31, 2024 (the “Effective Date”).
On January 3, 2023 the Board of Directors (the “Board”) of Cross Country Healthcare, Inc. (the “Company”) appointed Dwayne L. Allen as a director of the Board (the “Appointment”), with such Appointment to be effective immediately.
On November 16, 2022 the Board of Directors (the “Board”) of Cross Country Healthcare, Inc. (the “Company”) appointed Venkat Bhamidipati as a director of the Board (the “Appointment”).
James V. Redd III has been promoted to Senior Vice President and Chief Accounting Officer
On September 19, 2022 (the “Effective Date”), Cross Country Healthcare, Inc. (the “Company”) terminated the employment of Buffy S. White, Group President, Workforce Solutions of the Company, without cause and effective immediately.
On April 5, 2022, Daniel J. White became employed by Cross Country Healthcare, Inc. (“Cross Country” or the “Company”) as its Chief Commercial Officer.
will be appointed as a director of the Company (the “Appointment”)
Kevin C. Clark, Co-Founder and Chief Executive Officer (“CEO”) of the Company, will retire and transition from his current role as President and CEO of the Company to Chairman of the Board (the “Transition”).
John A. Martins, the Company’s current Group President, Delivery, will be promoted to President and CEO (the “Promotion”)
Max materiality 0.95 · Median 0.53 · Most common event other